MDXXF (Pharmala Biotech Holdings) Common Stock : $4.37 Mil (As of Nov. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Common Stock?

Pharmala Biotech Holdings's quarterly common stock increased from Feb. 2024 ($3.90 Mil) to Aug. 2024 ($4.17 Mil) and increased from Aug. 2024 ($4.17 Mil) to Nov. 2024 ($4.37 Mil).

Pharmala Biotech Holdings's annual common stock increased from Aug. 2022 ($3.74 Mil) to Aug. 2023 ($3.81 Mil) and increased from Aug. 2023 ($3.81 Mil) to Aug. 2024 ($4.17 Mil).

Pharmala Biotech Holdings Common Stock Historical Data

The historical data trend for Pharmala Biotech Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Common Stock Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Common Stock

1.74

3.74

3.81

4.17

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24	Nov24
Common Stock	Get a 7-Day Free Trial									3.81	3.84	3.90	4.17	4.37

Pharmala Biotech Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharmala Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

MDMA:Canada

Address

1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.